Gino Santini
Ca' Foscari University of Venice
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gino Santini.
British Journal of Haematology | 2000
D. Capelli; Gino Santini; C. de Souza; A. Poloni; G. Marino; M. Montanari; M. Lucesole; M. Brunori; D. Massidda; M. Offidani; P. Leoni; A. Olivieri
Amifostine (WR‐2721; Ethyol) is a well‐known cytoprotector, but a possible role in preventing extrahaematological toxicity after high‐dose therapy (HDT) has never been investigated. We compared two historical groups of patients who either received (group A, n = 35) or did not receive (group B, n = 33) amifostine (740 mg/m2) before high‐dose (HD) melphalan, followed by autologous infusion of peripheral blood progenitor cells (PBPCs). Amifostine was well tolerated at this dose level. Emesis grade 1–2 was the most important side‐effect, but the interruption of infusion was never required. The incidence and median duration of severe mucositis (grade 3–4) was 21% and 0 d (range 0–11 d) in group A and 53% and 7 d (range 0–11 d) in group B. The duration of analgesic therapy was also significantly lower in group A (0 d; range 0–12) than in group B (6 d, range 0–20) (P = 0·0001). Severe diarrhoea (3% vs. 25%; P = 0·01) and emesis (9% vs. 34%; P = 0·01) were also reduced in group A in comparison with group B. No differences were observed between the two groups for haematological recovery. This retrospective study strongly suggests that amifostine can reduce severe mucositis and the use of analgesic drugs in this setting. A randomized study is warranted to confirm these preliminary results.
Brazilian Journal of Medical and Biological Research | 2000
C.A. De Souza; Gino Santini; G. Marino; Sandro Nati; A. M. Congiu; Afonso Celso Vigorito; Eugenio Damasio
Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II study using amifostine as a protective drug against high-dose cyclophosphamide (HDCY) (7 g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and to reduce tumor burden. We enrolled 29 patients, 22 (75. 9%) affected by aggressive and 7 (24.1%) by indolent non-Hodgkins lymphoma (NHL), who were submitted to 58 infusions of amifostine and compared them with a historical group (33 patients) affected by aggressive NHL and treated with VACOP-B followed by HDCY. The most important results in favor of amifostine were the reduction of intensity of cardiac, pulmonary and hepatic toxicity, and a significant reduction of frequency and severity of mucositis (P = 0. 04). None of the 29 patients died in the protected group, while in the historical group 2/33 patients died because of cardiac or pulmonary toxicity and 2 patients stopped therapy due to toxicity. Amifostine did not prevent the aplastic phase following HDCY. PBPC collection and hematological recovery were adequate in both groups. The number of CFU-GM (colony-forming units-granulocyte/macrophage) colonies and mononuclear cells in the apheresis products was significantly higher in the amifostine group (P = 0.02 and 0.01, respectively). Side effects were mild and easily controlled. We conclude that amifostine protection should be useful in HDCY to protect normal tissues, with acceptable side effects.
Brazilian Journal of Medical and Biological Research | 2004
Gino Santini; C.C. de Souza; S. Aversa; Caterina Patti; L. Tedeschi; M. Candela; A. Olivieri; Teodoro Chisesi; A. Rubagotti; R. Centurioni; Valentina Nardi; M. Congiu; M. Gennaro; Mauro Truini
The objective of this multicenter prospective study was to determine the clinical efficacy and toxicity of a polychemotherapeutic third generation regimen, VACOP-B, with or without radiotherapy as front-line therapy in aggressive localized non-Hodgkins lymphoma. Ninety-three adult patients (47 males and 46 females, median age 45 years) with aggressive localized non-Hodgkins lymphoma, 43 in stage I and 50 in stage II (non-bulky), were included in the study. Stage I patients received VACOP-B for 6 weeks plus involved field radiotherapy and stage II patients received 12 weeks VACOP-B plus involved field radiotherapy on residual masses. Eighty-six (92.5%) achieved complete remission and 4 (4.3%) partial remission. Three patients (3.2%) were primarily resistant. Ten-year probability of survival, progression-free survival and disease-free survival were 87.3, 79.9 and 83.9%, respectively. Eighty-four patients are surviving at a median observation time of 57 months (range: 6-126). Statistical analysis showed no difference between stages I and II in terms of response, ten-year probability of survival, progression-free survival or disease-free survival. Side effects and toxicity were negligible and were similar in the two patient groups. The results of this prospective study suggest that 6 weeks of VACOP-B treatment plus radiotherapy may be the therapy of choice in stage I aggressive non-Hodgkins lymphoma. Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkins lymphoma.
Blood | 2004
Andrea Gallamini; Caterina Stelitano; Roberta Calvi; Monica Bellei; Daniele Mattei; Umberto Vitolo; Fortunato Morabito; Maurizio Martelli; Ercole Brusamolino; Emilio Iannitto; Francesco Zaja; Sergio Cortelazzo; Luigi Rigacci; Liliana Devizzi; Giuseppe Todeschini; Gino Santini; Maura Brugiatelli; Massimo Federico
Blood | 2002
Marco Ladetto; Paolo Corradini; Sonia Vallet; Fabio Benedetti; Umberto Vitolo; Maurizio Martelli; M. Brugiatelli; Paolo Coser; Alessio Perrotti; Ignazio Majolino; Giuseppe Fioritoni; Sergio Morandi; Maurizio Musso; Renato Zambello; Teodoro Chisesi; Nicola Di Renzo; Paolo Vivaldi; Alberto De Crescenzo; Andrea Gallamini; Flavia Salvi; Gino Santini; Carola Boccomini; Marco Sorio; Monica Astolfi; Daniela Drandi; Alessandro Pileri; Corrado Tarella
Cancer Treatment Reviews | 2007
Alexander Greb; Julia Bohlius; Sven Trelle; Daniel Schiefer; Carmino Antonio de Souza; Christian Gisselbrecht; Tanin Intragumtornchai; Ulrich Kaiser; Hanneke C. Kluin-Nelemans; Maurizio Martelli; Noel Milpied; Gino Santini; Leo F. Verdonck; Umberto Vitolo; Guido Schwarzer; Andreas Engert
Transfusion Science | 2000
José Francisco Comenalli Marques; Afonso Celso Vigorito; F.J.P. Aranha; Irene Lorand-Metze; Eliana Cristina Martins Miranda; E.C Lima Filho; M Valbonesi; Gino Santini; C.A. De Souza
Haematologica | 2001
C Guglielmi; Maurizio Martelli; Massimo Federico; Pier Luigi Zinzani; Umberto Vitolo; G Bellesi; Gino Santini; Corrado Tarella; Francesco Zallio; Patrizia Pregno; N. Di Renzo; L Resegotti; Italian Intergroup for Lymphomas
Revista Brasileira De Hematologia E Hemoterapia | 2008
Gino Santini; Teodoro Chisesi; Carmino Antonio de Souza
Hematology and Cell Therapy | 1999
Franco Mandelli; Francesco Lauria; Ignazio Majolino; Giovanna Meloni; Gino Santini; Robin Foà; Gianluigi Castoldi; Paolo Corradini; Brunangelo Falini; Stefano Pileri; Vincenzo Liso